Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ILK | Q13418 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514749 | 0.79 | ALDH1A1 (0.47) | HSD17B10ALDH1A1 | |
| SCHEMBL25344422 | 0.78 | HSD17B10 (0.36) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL29514029 | 0.78 | HSD17B10 (0.36) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL10874347 | 0.76 | HTT (0.43) | HSD17B10ALDH1A1LMNATDP1SMN1; SMN2 | |
| SCHEMBL19783248 | 0.74 | ALDH1A1 (0.42) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL21901453 | 0.74 | ALDH1A1 (0.42) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL30189744 | 0.74 | ALDH1A1 (0.42) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| Bromide SCHEMBL29611798 | 0.72 | ALDH1A1 (0.41) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| Bromide SCHEMBL21839505 | 0.72 | ALDH1A1 (0.41) | HSD17B10ALDH1A1LMNACYP3A4TDP1 | |
| SCHEMBL25346522 | 0.72 | CYP3A4 (0.45) | HSD17B10ALDH1A1LMNACYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011107710-A1 | USE OF RILUZOLE TO TREAT OR PREVENT THE ADVERSE EFFECTS OF ANTINEOPLASTIC AGENTS | UNIVERSITE D'AUVERGNE CLERMONT I (FR) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
| US-6713493-B2 | Use of nicergoline in the treatment of spasticity | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20020086875-A1 | Of neurological diseases involving attack of the pyramidal pathway such as: amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accident | DIB MICHEL (FR) | 2002-07-04 | — | — | US | disclosed |
| US-6380208-B2 | Use of nicergoline for treating spasticity | AVENTIS PHARMA S.A. (FR) | 2002-04-30 | — | — | US | disclosed |
| US-5656647-A | ADMINISTERING; USEFUL IN X-RAY THERAPY, EXPOSURE TO NUCLEAR RADITION AND ANTICARCINOGENIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 1997-08-12 | — | — | US | disclosed |
| US-5236940-A | Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders | RHONE-POULENC SANTE (FR) | 1993-08-17 | — | — | US | disclosed |
| US-4370338-A | ANTICONVULSANT, ANXIOLYTIC, AND HYPNOTIC; RILUZOLE | PHARMINDUSTRIE (FR) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | HSD17B10 1206/4885ALDH1A1 1872/4885LMNA 2765/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HSD17B10 1206/4885ALDH1A1 1872/4885LMNA 2765/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | HSD17B10 1101/4885ALDH1A1 1757/4885LMNA 3326/4885 |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | HSD17B10 1101/4885ALDH1A1 1757/4885LMNA 3326/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | HSD17B10 1117/4885ALDH1A1 1697/4885LMNA 3422/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HSD17B10 1206/4885ALDH1A1 1872/4885LMNA 2765/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | HSD17B10 159/4885ALDH1A1 491/4885LMNA 2621/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | HSD17B10 802/4885ALDH1A1 1046/4885LMNA 2940/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | HSD17B10 159/4885ALDH1A1 491/4885LMNA 2621/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | HSD17B10 802/4885ALDH1A1 1046/4885LMNA 2940/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | HSD17B10 1206/4885ALDH1A1 1872/4885LMNA 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.